Now, one type of weight-loss medication is proving helpful with another health issue. In a study published Feb. 12 in JAMA ...

The 5 mg risdiplam tablet provides the same efficacy and safety for spinal muscular atrophy as the currently available oral ...

Over the past nine years, patients with spinal muscular atrophy have seen the number of FDA-approved treatment options for ...

AnaptysBio’s Phase IIb trial of its rheumatoid arthritis (RA) treatment, rosinilimab, has seen some patients achieve the ...

A new study suggests that medications that have transformed the treatment of obesity may also help people drink less alcohol.

A paper published Wednesday offers the strongest evidence yet that this is more than just anecdote, or a placebo effect: It ...

The blockbuster drug semaglutide, better known as Ozempic for diabetes and Wegovy for obesity, could also help people cut ...

In the first clinical trial of its kind, people taking semaglutide drank less alcohol, adding to its promise of fighting addiction.

Sitting at a market capitalization of $159 billion, Amgen (AMGN) is a biotech powerhouse. Founded in 1980, it is one of the biggest names in the healthcare and biotech industry, with a strong history ...

Children with rheumatic diseases may face increased risks for COVID-19-related hospitalization, particularly those using glucocorticoids, rituximab, or mycophenolate.

AnaptysBio may have ended last year on a low, but 2025 is looking up with the news that its PD-1 agonist rosnilimab has ...

AnaptysBio shares surged 37% in premarket trading Wednesday after a mid-stage trial evaluating a rheumatoid arthritis treatment achieved its primary endpoint. Shares were recently trading around $17.